Evidence map›Paper›PMID 41041647›Full record

ReviewFrontiers in pharmacology2025

The influence of targeted therapies in the inner ear.

Tony Bonilla, Jake DiFatta, Esperanza Bas Infante, Stefania Goncalves

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tony BonillaNeuroscience Program, Howard College of Arts and Sciences, Samford University, Homewood, AL, United States.
Jake DiFattaDepartment of Otolaryngology-Head and Neck Surgery, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, United States.
Esperanza Bas InfanteInvestigational Drug Services, University of Miami, Coral Gables, FL, United States.
Stefania GoncalvesDepartment of Otolaryngology-Head and Neck Surgery, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scientific research has significantly propelled advancements in healthcare. One notable application is precision medicine, which seeks to analyze and comprehend disease pathology to offer personalized medical treatments to patients. Targeted oncology, a branch of precision medicine, focuses on identifying and targeting specific molecules that regulate cancer cells, thereby minimizing harm to healthy cells. Different types of targeted therapy against cancer include monoclonal antibodies and small molecules. This manuscript intends to provide an overview of the influence of these targeted oncology and non-oncology therapies on hearing. Furthermore, side effects including immune-related adverse events will be reviewed as potential causes of hearing deterioration in this patient population.

Indexed as

hearing lossmonoclonal antibodiesototoxicitysmall moleculestargeted therapies

Identifiers

PMID41041647
PMCPMC12484149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.